Quantity of Opioids for Acute Pain and Limit Unused Medication
NCT ID: NCT03953534
Last Updated: 2023-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2240 participants
OBSERVATIONAL
2019-05-06
2023-06-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Canada has no recommendations for the dosage, duration, or quantity of opioids that physicians should prescribe to manage acute pain at home. Physicians are therefore left guessing as to how much to prescribe when a patient with a condition like a fracture or renal colic is discharged from the emergency department. Our preliminary study showed that two-thirds of the pills from the initial opioid prescription to treat acute pain actually remained unused and were therefore available for potential misuse.
The investigators propose to determine how many opioid pills are consumed by patients who suffer from acute pain as they recover at home. The investigators will ask 2,560 patients (from 6 Canadian hospitals) to record their pain medication consumption in a 14-day diary. The investigators will also determine, their pain intensity level, whether or not they had new opioid prescriptions, and health services revisits. In case of missing information, patients will be contacted by phone at 2 weeks. The overall aim is to help emergency department physicians prescribe the right number of pills in order to manage patients' pain and at the same time reduce substantially leftovers available for potential misuse.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Appropriate Opioid Quantities for Acute Pain - Pharmacist Study
NCT04484610
How Much Opioids Do You Need After Your Emergency Department Visit
NCT02799004
Acute Pain Management in Patients on Opioid Replacement Therapy
NCT03933865
A Strategy to Reduce Opioid Drug Prescribing by Clinicians
NCT03809507
Patient Narcotic Requirements After Outpatient Otolaryngology Procedures
NCT03404518
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Prescription opioid overdoses have quadrupled in the last 15 years, and are now the leading cause of accidental death, surpassing motor vehicle accidents. The drastic rise in opioid prescription rates in Canada and the US could be the driving force behind this higher mortality. It was shown that 71% of opioid misusers (i.e., intentional users for nonmedical purposes) received their drugs through the diversion of unused prescribed opioids (transfer of opioids to someone other than the holder of the initial prescription). Emergency department (ED) physicians are among the top opioid prescribers for patients under 40, and there are currently no prospective studies on how many opioid pills should be prescribed to patients discharged from the ED with common pain conditions in order to limit unused pills. Preliminary results from our group revealed that two-thirds of the total prescribed opioids were not consumed and remained available for misuse.
Objectives
The ultimate goal of this research program is to decrease opioid misuse by lowering the quantity of unused medications. The primary objective of this project is to determine the quantity of opioids consumed during the acute pain phase (2 weeks) by ED-discharged patients treated for an acute pain condition. The secondary objectives are to inventory the quantity of opioids prescribed and unused after ED visits, use of co-analgesics, pain intensity, health services revisits during the 2-week follow-up, and chronic pain prevalence at 3 months.
Methods
The investigators propose a multicentre prospective observational cohort study in 2,560 consecutive ED patients recruited from 6 Canadian hospitals. The study will include patients aged ≥18 years, treated for an acute pain condition present for less than 2 weeks (usual acute pain definition), and discharged from the ED with an opioid prescription. Pain at triage and at ED discharged, diagnosis, and complete pain medication prescription will be initially listed. Patients will complete a 14-day electronic diary using the REDCap web-based system to document their daily pain medication consumption, pain intensity, new opioid prescriptions, and health services revisits. Patients will also answer questionnaires at 2 weeks and 3 months for our various secondary objectives. To validate the patient self-report opioid consumption, a randomized subset of patients will come back to the emergency for a follow-up visit and a manual count of the remaining opioids. As mitigation strategies (validated in our pilot study), non-responders to the diary will be contacted by phone at 2 weeks to answered questions summing diary information, and paper versions will be available for patients without Internet access.
Sample size estimation
The sample size was calculated to obtain an accurate estimate of the mean quantity of 5 mg morphine pill equivalent that patients will consume during the first 2 weeks after ED visit for each pain condition (primary objective). Our preliminary study was used to determine the standard deviation of opioids consumed after discharge from ED (SD=16). To estimate the mean 5 mg morphine pill equivalent consumed for each of the five pain conditions (acute back pain, fracture, sprain/contusion, renal colic, and other) with a 95%CI margin of error of 1.5 pills (or \~10% of the SD) with a standard deviation of 16 pills, each diagnostic category requires 440 patients. With the 14% attrition rate observed during our pilot study at two weeks, a total of 2,560 patients will be recruited (512 patients - 72 lost to follow-up = 440 patients per pain condition). Sample size calculations were performed using PASS (Power Analysis \& Sample Size software, version 11.0: NCSS Statistical Software).
Feasibility
The investigators demonstrated the study feasibility in a successful pilot study with 627 patients at our academic ED. Additionally, our project brings together a committed, multidisciplinary research team, and all proposed study sites have collaborated previously on large multicentre studies. Finally, all instruments have been successfully tested, allowing rapid study implementation.
Impact
Our results will determine the quantity of opioids consumed during the acute pain phase (2 weeks) to ED-discharged patients treated for acute pain conditions. Our team members from relevant provincial and national stakeholders and patient associations, our strong evidence, and our extensive knowledge transfer strategy have the potential to impact physicians' opioid prescription practices. Consequently, fewer unused prescription opioids should lead to a substantial decrease in the currently high rate of opioid misuse.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute pain for less than 2 weeks
Exclusion Criteria
* Chronic pain under treatment
* Active Neoplasia
* Follow-up impossible / Unable to complete agenda
* Already on opioids
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen's University
OTHER
Maisonneuve-Rosemont Hospital
OTHER
Sunnybrook Health Sciences Centre
OTHER
Hopital de l'Enfant-Jesus
OTHER
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Raoul Daoust
Clinician Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raoul Daoust, MD MSc
Role: PRINCIPAL_INVESTIGATOR
Université de Montréal
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kingston General Hospital
Kingston, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Hôpital du Sacré-Coeur de Montréal
Montreal, Quebec, Canada
Hôpital régional de Saint-Jérôme
Saint-Jérôme, Quebec, Canada
Hôpital de l'Enfant-Jésus
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Daoust R, Paquet J, Perry JJ, Yan JW, Williamson D, Castonguay V, Lavigne G, Rouleau D, Lessard J, Cournoyer A; OPUM research group. How Does Self-Declared Chronic Pain Compare to Other Definitions? A Prospective Multicenter Study. Pain Res Manag. 2025 Jun 19;2025:5556400. doi: 10.1155/prm/5556400. eCollection 2025.
Daoust R, Paquet J, Emond M, Iseppon M, Williamson D, Yan JW, Perry JJ, Huard V, Lavigne G, Lee J, Lessard J, Lang E, Cournoyer A; Quantity of Opioids for Acute Pain and Limit Unused Medication (OPUM) group on behalf of the Network of Canadian Emergency Researchers. Opioid prescribing requirements to minimize unused medications after an emergency department visit for acute pain: a prospective cohort study. CMAJ. 2024 Jul 14;196(25):E866-E874. doi: 10.1503/cmaj.231640.
Daoust R, Paquet J, Williamson D, Perry JJ, Iseppon M, Castonguay V, Morris J, Cournoyer A. Accuracy of a self-report prescription opioid use diary for patients discharge from the emergency department with acute pain: a multicentre prospective cohort study. BMJ Open. 2022 Oct 28;12(10):e062984. doi: 10.1136/bmjopen-2022-062984.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PJT-159808
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2019-1684
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.